Group 6E: HR+, HER2-low, & HER2-0 Breast Cancer

Poster #PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy.

Poster #PO4-05-06: Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment.